AU2003254120B2 - Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof - Google Patents

Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof Download PDF

Info

Publication number
AU2003254120B2
AU2003254120B2 AU2003254120A AU2003254120A AU2003254120B2 AU 2003254120 B2 AU2003254120 B2 AU 2003254120B2 AU 2003254120 A AU2003254120 A AU 2003254120A AU 2003254120 A AU2003254120 A AU 2003254120A AU 2003254120 B2 AU2003254120 B2 AU 2003254120B2
Authority
AU
Australia
Prior art keywords
cephalotaxine
angiogenic
host
disease
angiogenic disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003254120A
Other languages
English (en)
Other versions
AU2003254120A1 (en
Inventor
Dennis M. Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of AU2003254120A1 publication Critical patent/AU2003254120A1/en
Assigned to CHEMGENEX PHARMACEUTICALS LIMITED reassignment CHEMGENEX PHARMACEUTICALS LIMITED Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Application granted granted Critical
Publication of AU2003254120B2 publication Critical patent/AU2003254120B2/en
Assigned to CHEMGENEX PHARMACEUTICALS, INC. reassignment CHEMGENEX PHARMACEUTICALS, INC. Request for Assignment Assignors: CHEMGENEX PHARMACEUTICALS LIMITED
Assigned to TEVA PHARAMCEUTICALS INTERNATIONAL GMBH reassignment TEVA PHARAMCEUTICALS INTERNATIONAL GMBH Request for Assignment Assignors: CHEMGENEX PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2003254120A 2002-07-22 2003-07-22 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof Ceased AU2003254120B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39765702P 2002-07-22 2002-07-22
US60/397,657 2002-07-22
PCT/US2003/022926 WO2004009030A2 (en) 2002-07-22 2003-07-22 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2003254120A1 AU2003254120A1 (en) 2004-02-09
AU2003254120B2 true AU2003254120B2 (en) 2009-09-10

Family

ID=30771096

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003254120A Ceased AU2003254120B2 (en) 2002-07-22 2003-07-22 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof

Country Status (7)

Country Link
US (2) US7642252B2 (enExample)
EP (1) EP1539179B1 (enExample)
JP (1) JP2005537282A (enExample)
AU (1) AU2003254120B2 (enExample)
CA (1) CA2493544A1 (enExample)
ES (1) ES2572145T3 (enExample)
WO (1) WO2004009030A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
WO2005087221A1 (en) * 2004-03-15 2005-09-22 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
EP1765341A4 (en) * 2004-06-04 2010-04-14 Chemgenex Pharmaceuticals Inc PROCESS FOR TREATING PROLIFERATIVE CELL DISEASE USING NAPHTHALIMIDE AND PARP-1 INHIBITORS
EP1848391A2 (en) * 2005-02-10 2007-10-31 ChemGenex Pharmaceuticals, Inc. Medical devices
CN103285015B (zh) * 2007-04-13 2016-04-27 化学基因制药公司 三尖杉碱口服剂型
US8466142B2 (en) 2008-03-03 2013-06-18 Sloan-Kettering Institute For Cancer Research Cephalotaxus esters, methods of synthesis, and uses thereof
US20120283306A1 (en) * 2011-04-27 2012-11-08 Georgia Health Sciences University Mouse model for avm
KR102066684B1 (ko) * 2018-02-19 2020-01-15 가천대학교 산학협력단 개비자나무 추출물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 자가면역질환의 예방 또는 치료용 조성물
KR102174166B1 (ko) * 2018-12-13 2020-11-04 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
KR102066683B1 (ko) * 2019-09-16 2020-01-15 가천대학교 산학협력단 개비자나무 추출물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 자가면역질환의 예방 또는 치료용 조성물
KR102209386B1 (ko) * 2020-01-09 2021-02-01 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 대사질환 예방 또는 치료용 약학조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068098A2 (en) * 2000-03-15 2001-09-20 Chemgenex Therapeutics, Inc. Cephalotaxine alkaloid combination compositions and uses thereof
US20010049349A1 (en) * 1997-07-01 2001-12-06 Rebecca Chinery Antioxidant enhancement of therapy for hyperproliferative conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3793454A (en) * 1971-11-12 1974-02-19 Us Agriculture Harringtonine and isopharringtonine for treating l1210 or p388 leukemic tumors in mice
US4152214A (en) * 1977-10-07 1979-05-01 The United States Of America As Represented By The Secretary Of Agriculture Production of homodeoxyharringtonine and other cephalotaxine esters by tissue culture
JPS5835146A (ja) 1981-08-28 1983-03-01 Isukura Sangyo Kk ２−ケト−６−メチル−５−ヘプテン酸エチルエステルの製造方法
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
CA2188813C (en) 1994-04-26 2010-08-03 Michael S. O'reilly Angiostatin protein, nucleic acids encoding the same and methods of detection
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
JP4979157B2 (ja) * 1998-09-09 2012-07-18 バイオリポックス アーべー 置換されたγ−フェニル−Δ−ラクトンおよびそのアナログならびにこれらに関する使用
US6465424B1 (en) * 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
EP1267913A2 (en) * 1999-11-12 2003-01-02 EntreMed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
EP1274458B1 (en) * 2000-04-12 2005-09-28 ChemGenex Pharmaceuticals, Inc. Compositions containing a naphthalmide and an antiproliferative agent
WO2002003904A1 (en) 2000-06-21 2002-01-17 Shigeo Takizawa Lift device capable of performing activating motion
AU7940500A (en) 2000-10-17 2002-04-29 Oncopharm Corp New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents
US20040034026A1 (en) * 2000-11-22 2004-02-19 Wood Jeannette M Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
CN100396286C (zh) * 2002-12-30 2008-06-25 北京大学第一医院 高三尖杉酯碱和三尖杉酯碱在制备抑制血管生成药物中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049349A1 (en) * 1997-07-01 2001-12-06 Rebecca Chinery Antioxidant enhancement of therapy for hyperproliferative conditions
WO2001068098A2 (en) * 2000-03-15 2001-09-20 Chemgenex Therapeutics, Inc. Cephalotaxine alkaloid combination compositions and uses thereof
US20020032190A1 (en) * 2000-03-15 2002-03-14 Brown Dennis M. Cephalotaxine alkaloid compositions and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anticancer Research (1988) 8: 343-346 *
Cancer Chemother Pharmacol (1993) 33(2): 149-153 *
Eur J Cancer Clin Oncol (1989) Feb 25(2):2263-269 *
J Cell Physiol (1991) Sept 148(3):464-471 *

Also Published As

Publication number Publication date
EP1539179B1 (en) 2016-03-02
US7642252B2 (en) 2010-01-05
WO2004009030A2 (en) 2004-01-29
AU2003254120A1 (en) 2004-02-09
CA2493544A1 (en) 2004-01-29
WO2004009030A3 (en) 2004-09-10
JP2005537282A (ja) 2005-12-08
EP1539179A2 (en) 2005-06-15
US20040077629A1 (en) 2004-04-22
ES2572145T3 (es) 2016-05-30
US20090270368A1 (en) 2009-10-29
EP1539179A4 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
US20090270368A1 (en) Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
JP6868014B2 (ja) 翼状片を治療するための組成物及び方法
TWI532480B (zh) 以斑馬魚模組進行藥物篩選之方法及篩選所得藥物
EA006097B1 (ru) Способ лечения раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
JP2000514402A (ja) Ｖｅｇｆに関連する目の病気に関する治療処置
CN101528038A (zh) 用于治疗与雌激素受体相关的疾病的化合物和方法
JP5435946B2 (ja) 疾患を処置するためのヘッジホッグ経路アンタゴニスト
CN108883096A (zh) 脉络膜新生血管抑制剂或玻璃膜疣抑制剂及其评价或筛选方法
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
KR101794713B1 (ko) 황반변성 예방 또는 치료용 약학조성물
US20030232741A1 (en) Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
TW200538466A (en) Methods for controlling angiogenesis and cell proliferation
CN104736151A (zh) 纤维化的柚皮素和积雪草酸组合治疗
JP7174444B2 (ja) 前立腺肥大症および尿路疾患におけるマルチキナーゼ阻害剤および使用
HK1077019B (en) Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
CN102038673A (zh) 羟基苯并吡喃酮类化合物在制备治疗白血病药物中的应用
CN101068548B (zh) 用于减少、稳定富含脂质的斑块和/或防止富含脂质的斑块破裂的方法
CN107496426A (zh) 含伊马替尼或其药学上可接受的盐作为有效成分的用于治疗或预防血管渗透性疾病的组合物
JP5024967B2 (ja) 細胞増殖および血管形成を阻害するための方法および組成物
WO2021180055A1 (zh) 一种brd4抑制剂的用途
JP7233087B2 (ja) 抗動脈硬化剤
WO2016115840A1 (zh) 二苯乙烯苷在制备tlr4固有免疫系统的抑制剂中的应用
HK40069641A (en) Compositions and methods for treating pterygium
WO2009104152A1 (en) Combination treatment for ovarian cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT TO CHEMGENEX PHARMACEUTICALS LIMITED

PC1 Assignment before grant (sect. 113)

Owner name: CHEMGENEX PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): CHEMGENEX PHARMACEUTICALS LIMITED

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TEVA PHARAMCEUTICALS INTERNATIONAL GMBH

Free format text: FORMER OWNER WAS: CHEMGENEX PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired